Table 2.

Molecular characteristics of post-crizotinib biopsies and individual responses to crizotinib and ceritinib

PatientCrizotinib PFS (mo)Crizotinib beyond progression (mo)ALK resistance mutations or amplification in crizotinib-resistant biopsyInterval lines of therapyCrizotinib-ceritinib interval (mo)Ceritinib PFS (mo)
118.20.4C1156Y00.32.4
24.61.6ALK amplification00.84.3
37.53.4L1196M00.73.9
411.20.8NM24.48.2
532.03.3S1206Y00.814.8
66.15.4NM00.59.7
718.59.2NM00.316.2 a
88.15.2L1196M111.010.8
96.92.1NM210.211.3
109.80.0NM02.018.0
1114.50.0L1196M00.65.4
127.41.0ALK amplification00.99.5
1313.50.1NM01.65.2
143.12.5NM00.31.2
152.60.2NM00.56.5
168.10.0NM115.72.7
1710.82.0G1269A, 1151Tins13.62.7
187.11.3NM00.32.9
192.81.4NM11.51.8
205.61.5NM00.34.0
2120.60.0NM323.18.2
2220.47.4NM00.516.8
2311.51.0L1196M00.88.9

Abbreviation: NM, no ALK resistance mutation.

  • aCensored.